Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including lenacapavir—HIV’s ability to evolve resistance to the breakthrough antiviral.

Lenacapavir (LEN) is an antiviral medication used to treat and prevent HIV/AIDS and was first approved for individuals with ...

Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...

The common cold is typically caused by viruses, most often rhinoviruses, which infect the upper respiratory tract (nose and throat). 1 Zinc has been reported to block the replication of rhinovirus. By ...

Across the world, only a few dozen people appear to carry a genetic glitch that lets them brush off viruses that flatten ...